Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.
Biochem Pharmacol · 2025
Last updated 2026-05-28In a rat study, clozapine (20 mg/kg) impaired brain function, damaged mitochondria, and reduced energy production in the hippocampus and prefrontal cortex. The GLP-1 drug liraglutide (0.4 mg/kg) reversed these effects by restoring mitochondrial function and energy metabolism, while a GLP-1 blocker canceled out these benefits.
AI summary of the abstract below.
| Journal | Biochem Pharmacol, 2025 |
|---|---|
| Citations | 3 |
| Molecules | liraglutide |
| Conditions studied | Alzheimers, Depression, Bipolar Disorder |
Abstract
Chronic use of antipsychotics for schizophrenia (SCZ) often causes metabolic disturbances that exacerbate cognitive impairment, and the underlying mechanisms remain unclear. As a classic antipsychotic, the metabolic toxicity of clozapine (CLZ) has been associated with the novel target progesterone receptor membrane component 1 (PGRMC1), which interacts with the glucagon-like peptide-1 receptor (GLP-1R). This study aimed to investigate the role of the GLP-1R signaling pathway in CLZ-induced metabolic toxicity and explore its potential therapeutic implications. Rats (n = 7/group) were treated with CLZ (20 mg/kg, i.p.), the GLP-1R agonist LIRA (LIRA, 0.4 mg/kg, i.p.), the GLP-1R antagonist Exendin9-39 (Ex9, 50 μg/kg, i.p.) or their combinations for three weeks, and then subjected to assess the cognitive function, neuronal activity, mitochondrial integrity and signaling pathways. The results demonstrated that CLZ impaired cognitive function and induced neuronal apoptosis, as shown by the behavioral performance and morphology staining. Electron microscopy imaging and related detections also revealed that CLZ damaged mitochondrial structure and function by decreasing TCA cycle intermediates, which resulted in reduced adenosine triphosphate (ATP) production and increased oxidative stress in both the hippocampus and prefrontal cortex. Western blotting results showed that CLZ inhibited the PGRMC1/GLP-1R/Mfn2 signaling pathway, whereas combination of LIRA treatment reversed the inhibitory changes, presenting restorative effects on CLZ-induced mitochondrial dysfunction and disturbed energy metabolism. Adversely, further addition toEx9 could abolish the protective effects of LIRA. This study highlights the importance of PGRMC1/GLP-1R/Mfn2 signaling in antipsychotic-induced neurotoxicity in mitochondria, suggesting that upregulating this pathway by GLP-1R agonist may provide a novel adjunctive therapeutic approach for SCZ.
Verbatim abstract via PubMed 40588078 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.